Abstract Presentation

FIRST-IN-HUMAN STUDY OF SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SAR443820, A CENTRALLY PENETRANT RIPK1 INHIBITOR IN HEALTHY PARTICIPANTS